Key Facts
• Regencell Bioscience Holdings’ stock rose over 46,000% in 2025.
• The company specializes in herbal medicine and has no recorded revenue or profit.
• Market value increased from $53 million to $30 billion in one year.
• Fiscal year 2024 net loss was $4.4 million, a 28% improvement from the previous year.
• A 38-to-1 stock split was approved and executed on June 16, 2025.
• Stock price surged 283% in one day post-split, triggering 10 trading halts.
• Only 6% of nearly 500 million shares are publicly tradable.
• CEO Yat-Guy Au holds 86% of the company’s shares.
• Regencell is listed on Nasdaq since 2021 and remains in the R&D phase.
• The company is registered in the Cayman Islands.
Summary
Regencell Bioscience Holdings, a Hong Kong-based biotech firm specializing in herbal medicine, has seen its stock skyrocket over 46,000% in 2025 despite no revenue or profit. The company’s market value surged from $53 million to $30 billion within a year. A 38-to-1 stock split on June 16, 2025, led to a 283% single-day stock price increase, triggering multiple trading halts. With only 6% of shares publicly tradable, CEO Yat-Guy Au controls 86% of the company’s stock. Listed on Nasdaq since 2021, Regencell remains in the research and development phase, with its latest fiscal year showing a $4.4 million net loss, a 28% improvement from the prior year.
